Casey Rendon
Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1578004792
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 44.9% of the total. 2025 is the largest year on record at $4,887, more than ten times the $236 reported in 2021.
Across 58 payments — averaging $159.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$4K
- Medtronic$1K
- Abbott$934
- Novo Nordisk$797
- Dexcom, Inc.$431
- Boehringer Ingelheim$243
- plus $1K from 11 others
What the payments were for
- Consulting fees$3,20035%
- Travel & lodging$1,67518%
- Food & beverage$4,39147%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 8 | $4,157 |
| Medtronic | 13 | $1,377 |
| Abbott | 8 | $934 |
| Novo Nordisk | 7 | $797 |
| Dexcom, Inc. | 7 | $431 |
| Boehringer Ingelheim | 2 | $243 |
| Corcept Therapeutics | 2 | $219 |
| Amryt Pharma Holdings Ltd | 1 | $178 |
| BETA Bionics, Inc. | 2 | $157 |
| Sanofi-aventis U.S. LLC | 1 | $144 |
| Amgen | 1 | $122 |
| Xeris Pharmaceuticals, Inc. | 1 | $118 |
| Lifescan, Inc. | 1 | $109 |
| Angiodynamics, Inc. | 1 | $89 |
| Ascendis Pharma Endocrinology Inc | 1 | $81 |
| Lilly USA, LLC | 1 | $70 |
| Tandem Diabetes Care, Inc. | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$3,935
- MINIMED 780G$952
- FREESTYLE LIBRE 3$726
- iLet Bionic Pancreas$416
- Ozempic$361
- DEXCOM G6 TRANSMITTER$275
- JARDIANCE$243
- RYBELSUS$229
- MYCAPSSA$178
- TZIELD$144
- Afinion 2$132
- Korlym$123
- TEPEZZA$122
- GVOKE PFS$118
How this compares
$9,266 in reported general payments places this provider in the 75th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 20 | $99,869 |
| MounjaroTirzepatide | 41 | $54,902 |
| JardianceEmpagliflozin | 32 | $49,768 |
| OzempicSemaglutide | 29 | $46,279 |
| Teriparatide | 14 | $38,183 |
| TrulicityDulaglutide | 18 | $16,180 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,355 |
| Hydrocortisone | 31 | $2,270 |
| LantusInsulin Glargine,hum.Rec.Anlog | 22 | $2,215 |
| HumalogInsulin Lispro | 12 | $1,586 |
| Insulin Lispro | 16 | $1,440 |
| Testosterone | 14 | $968 |
| Levothyroxine Sodium | 93 | $816 |
| Methimazole | 37 | $681 |
| Testosterone Cypionate | 12 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro, Trulicity, Humalog, Insulin Lispro | $70 | $173,976107 claims |
| Boehringer IngelheimJardiance | $243 | $49,76832 claims |
| Novo NordiskOzempic | $797 | $46,27929 claims |
| Sanofi-aventis U.S. LLCLantus | $144 | $2,21522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Tucson
- Muhammad SethiTucson$670K
- Karen HerbstTucson$200K
- Nora BarsonyTucson$121K
- Maria PosadasTucson$24K
- Dorota PucykTucson$15K
- Neda EbrahimiTucson$11K
- Jonathan InselTucson$7K
- Roshanak HabibiTucson$7K
- Ramiro Cardenas LaraTucson$6K
- Cynthia Rivas PajueloTucson$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.